Moderna cut its 2026 sales forecast to $3B-$3.5B and posted a $1.2B Q2 loss. The RSV vaccine is now on the market. Cash burn is mounting as sales wane.
Moderna cut its full-year 2026 sales forecast to $3 billion to $3.5 billion, down from a prior range of $3.5 billion to $4.5 billion. COVID vaccine sales plunged in the second quarter, with revenue falling to $286 million from $1.3 billion a year earlier. The company posted a net loss of $1.2 billion, or $3.16 a share, compared with a loss of $1.3 billion, or $3.31 a share, in the same period last year. Cash and investments stood at $8.2 billion at the end of June, down from $9.4 billion at the start of 2025.
CEO Stéphane Bancel called the current period a "transition year" as the company launches its first products beyond COVID. The RSV vaccine, approved in the U.S. earlier this year, is now on the market. The stock has fallen more than 60% over the past year after the market repriced the company for a smaller revenue base and years of heavy R&D spending. The MRNA stock page carries an Alpha Score of 40 out of 100, a Mixed rating.
The new guidance range translates to second-half product sales of roughly $2.1 billion to $2.6 billion. Moderna expects to end 2026 with roughly $7 billion in cash.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.